- 1st spin-off company of the Faculty of Medicine MUNI , spin-off company of the Masaryk University.- Focusing on the research and development of the eHealth solutions for Mental Health.- Close cooperation with the Ministry of Health, State Health Institute, Health Insurance companies.MOST PROUD OF:- New product launch: MyWay analytix® , created new category of therapeutic screening of the Mental Health for individuals and organizations. Introducing new methodology of 14… Show more - 1st spin-off company of the Faculty of Medicine MUNI , spin-off company of the Masaryk University.- Focusing on the research and development of the eHealth solutions for Mental Health.- Close cooperation with the Ministry of Health, State Health Institute, Health Insurance companies.MOST PROUD OF:- New product launch: MyWay analytix® , created new category of therapeutic screening of the Mental Health for individuals and organizations. Introducing new methodology of 14 Mental Health Indicators™. - MyWay analytix® preparation for the first implementation and piloting in large scale companies. - Negotiating subsidy from the Heath Insurance companies. Show less

- Reporting to Regional Oncology Director, from Jan 2021 to Managing Director Czech Rep.- Yearly revenue: $20M, 2025 projection: $60M. Full P&L res.- Leading a team of 9 + 2 Medical Advisors + 1 Digital Manager- Member of the Czech Senior Leadership TeamMOST PROUD OF:- Created highly motivated performing cross- functional team, reached growth in 2020: +122 % YoY (+$6M)- High contribution to gain 5 new indications reimbursed in 2 years- Significantly improved… Show more - Reporting to Regional Oncology Director, from Jan 2021 to Managing Director Czech Rep.- Yearly revenue: $20M, 2025 projection: $60M. Full P&L res.- Leading a team of 9 + 2 Medical Advisors + 1 Digital Manager- Member of the Czech Senior Leadership TeamMOST PROUD OF:- Created highly motivated performing cross- functional team, reached growth in 2020: +122 % YoY (+$6M)- High contribution to gain 5 new indications reimbursed in 2 years- Significantly improved MSD perception, reached highest NPS within leading oncology companies- Led Agile transformation achieved effective WoW (less meetings, increased motivation and empowerment)- Achieved leadership in digital communication among leading oncology companies- Create and executed the Lighthouse project to improve lung cancer patient journey via improving quality of diagnostic (bronchoscopy) using innovative tools (Endo VR) and increasing awareness among lay public: Lung don’t hurt campaign incl. TVC Show less

Marketing and sales responsibility for Seretide, hospital business, established and specialty brand portfolio and HIV- Reporting to General Manager Czech Rep.- Yearly revenue: $45M (52 % of total GSK sales). Full P&L res. - Leading a team of 8- Member of the Czech Senior Leadership TeamMOST PROUD OF:- Transformed business unit into highly performing team reflecting future needs: YoY upside +$3M - HIV successful launch delivered upside +$1M vs plan- Managed… Show more Marketing and sales responsibility for Seretide, hospital business, established and specialty brand portfolio and HIV- Reporting to General Manager Czech Rep.- Yearly revenue: $45M (52 % of total GSK sales). Full P&L res. - Leading a team of 8- Member of the Czech Senior Leadership TeamMOST PROUD OF:- Transformed business unit into highly performing team reflecting future needs: YoY upside +$3M - HIV successful launch delivered upside +$1M vs plan- Managed several organizational changes to better reflect the future needs - Established pricing and discount approval and evaluation process ( discount schemes, pricing request RACI...)- Improve LOC Commercial and logistic process leaded to less OOS. Show less

Yearly revenue: $29M Strategic plan development and execution to maintain Seretide MS after Lost of Exclusivity including HCPs, Hospital Management and PharmaciesMOST PROUD OF:- Reached the highest SoV (Sep. 2014) and gained MS +2.69ppts MoM. Campaign rolled out into other cluster countries

Yearly Revenue: $10M Otrivin negative sell out trend turnaround via new strategy: +32 % YoY

- Leading a team of 2- Increased innovation volume from 0.04 % in 2009 to 7.5 % in 2011- “Staropramen 11” development & launch: reached sales +44 % vs planMOST PROUD OF: - Staropramen Cool Lemon - leader of the project: product development, packaging design and communication development. The most successful Innovation within Staropramen history Achieved + 140% higher volume vs. plan (26M 0.5l beer sold in first year). Communication awarded by silver Effie.- Changing… Show more - Leading a team of 2- Increased innovation volume from 0.04 % in 2009 to 7.5 % in 2011- “Staropramen 11” development & launch: reached sales +44 % vs planMOST PROUD OF: - Staropramen Cool Lemon - leader of the project: product development, packaging design and communication development. The most successful Innovation within Staropramen history Achieved + 140% higher volume vs. plan (26M 0.5l beer sold in first year). Communication awarded by silver Effie.- Changing consumers’ habits and preferences: “Branik Dvoulitr” PET launch created a new segment. 6M of 2l units sold in first year Show less

Australia, Sydney